Beth Pletcher

Dr. Beth Pletcher

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2021 in Human Genetics
Verified
Journal Article
Closed access
PDF file
JCJuliette Coursimault
Juliette Coursimault
AGAnne-Marie Guerrot
Anne-Marie Guerrot
MMMichelle M. Morrow
Michelle M. Morrow
CSCatherine Schramm
Catherine Schramm
FZFrancisca Millan Zamora
Francisca Millan Zamora
FLFrançois Lecoquierre
François Lecoquierre

8 June 2022 in Clinical Genetics
Verified
Journal Article
Open access
MCMaria B. Christensen
Maria B. Christensen
ALAmanda M Levy
Amanda M Levy
NMNazanin A. Mohammadi
Nazanin A. Mohammadi
MNMarcello Niceta
Marcello Niceta
RKRauan Kaiyrzhanov
Rauan Kaiyrzhanov
Zeynep TümerZeynep Tümer
Zeynep Tümer
Biallelic variants of the gene encoding for the zinc‐finger protein 142 (ZNF142) have recently been associated with intellectual disability (ID), speech impairment, seizures, and movement disorders in nine individuals from five families. In this study, we obtained phenotype and genotype information of 26 further individuals from 16 families. Among the 27 different ZNF142 variants identified in the total of 35 individuals only four were missense. Missense variants may give a milder phenotype by changing the local structure of ZF motifs as suggested by protein modeling; but this correlation should be validated in larger cohorts and pathogenicity of the missense variants should be investigated with functional studies. Clinical features of the 35 individuals suggest that biallelic ZNF142 variants lead to a syndromic neurodevelopmental disorder with mild to moderate ID, varying degrees of delay in language and gross motor development, early onset seizures, hypotonia, behavioral features, movement disorders, and facial dysmorphism. The differences in symptom frequencies observed in the unpublished individuals compared to those of published, and recognition of previously underemphasized facial features are likely to be due to the small sizes of the previous cohorts, which underlines the importance of larger cohorts for the phenotype descriptions of rare genetic disorders.

27 February 2020 in Journal of Genetic Counseling
Verified
Journal Article
Closed access
PDF file
ATAllysa Tuite
Allysa Tuite
MPMichelle Dalla Piazza
Michelle Dalla Piazza
KBKristyn Brandi
Kristyn Brandi
BPBeth Pletcher
Beth Pletcher

19 September 2020 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
MKMia Kunitomo
Mia Kunitomo
AKAditi Khokhar
Aditi Khokhar
CKChristina Kresge
Christina Kresge
FEFolorunsho Edobor‐Osula
Folorunsho Edobor‐Osula
BPBeth Pletcher
Beth Pletcher

1 August 2019 in Heliyon
Verified
Journal Article
Open access
HAHael F. Abdulrazeq
Hael F. Abdulrazeq
IGIra M. Goldstein
Ira M. Goldstein
SESamer T. Elsamna
Samer T. Elsamna
BPBeth Pletcher
Beth Pletcher

Verified
Journal Article
Open access
PDF file
CMCaitlin Menello
Caitlin Menello
SPShaney Pressley
Shaney Pressley
MSMadeline Steffensen
Madeline Steffensen
SSSarah Schmidt
Sarah Schmidt
HPHelio Pedro
Helio Pedro
Can FiciciogluCan Ficicioglu
Can Ficicioglu
Gaucher disease (GD) is a lysosomal storage disorder (LSD) characterized by glycosphingolipid accumulation. Age of symptomonset and disease progression varies across types of disease. Newborn screening (NBS) for Gaucher disease facilitates early identification of affected individuals and enables pre-symptomatic monitoring with the goal of starting therapies early and improving clinical outcomes. This multi-center study involved New Jersey NBS referral centers. Data regarding initial NBS results, confirmatory testing, diagnosis, and treatment were collected. For patients on therapy, monitoring biomarkers and exam findings are available as of the last clinical evaluation. Between July 2019 and December 2023, 438,515 newborns were screened, with 60 screen-positive cases. Of those positive screens, 19 cases with positive screens did not undergo confirmatory testing due to parental refusal, loss to follow-up, or death; 23 cases were false positives; 14 newborns were diagnosed with GD type I; 2 newborns were diagnosed with suspected type I GD; 2 newborns were diagnosed with GD type II; and 1 case is still pending. Three type I GD patients started enzyme replacement therapy, with the youngest starting at 28 months of age. Post-treatment data are available for these individuals. One type II case was referred to experimental gene therapy, and one was started on ERT. Our results demonstrate that NBS for GD is a valuable public health tool that can facilitate early diagnosis and intervention.